The New Era in Cancer Research

For many years, discoveries about the genetic determinants of cancer appeared to be having only minor effects on efforts to control the disease in the clinic. Following advances made over the past decade, however, a description of cancer in molecular terms seems increasingly likely to improve the ways in which human cancers are detected, classified, monitored, and (especially) treated. Achieving the medical promise of this new era in cancer research will require a deeper understanding of the biology of cancer and imaginative application of new knowledge in the clinic, as well as political, social, and cultural changes.

[1]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[2]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[3]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[4]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[5]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[6]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[7]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[8]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[9]  Vasilis Ntziachristos,et al.  Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Moses,et al.  Tumor-stroma interactions. , 2005, Current opinion in genetics & development.

[11]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[13]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[14]  H. Varmus,et al.  Oncogenes come of age. , 2005, Cold Spring Harbor symposia on quantitative biology.

[15]  L. Staudt,et al.  The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.

[16]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[17]  G. DeFriese,et al.  The New York Times , 2020, Publishing for Libraries.

[18]  Bonnie F. Sloane,et al.  Cysteine cathepsins in human cancer , 2004, Biological chemistry.

[19]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[20]  D. Felsher.  Reversibility of oncogene-induced cancer. , 2004, Current opinion in genetics & development.

[21]  I. Weissman,et al.  Therapeutic implications of cancer stem cells. , 2004, Current opinion in genetics & development.

[22]  H. Varmus,et al.  Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Connors,et al.  The Washington Post , 2003 .

[25]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[26]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[27]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[28]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[29]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[30]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[31]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[32]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[33]  J. Bishop.  Molecular themes in oncogenesis , 1991, Cell.

[34]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[35]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[36]  J. Burchenal,et al.  Treatment of acute leukemia. , 1956, Pediatrics.

[37]  D. Tayloe,et al.  Pediatrics , 1927, The Indian Medical Gazette.